BSE
ZYDUSLIFE

Zydus Lifesciences Ltd

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Zydus Lifesciences Ltd Stock Price

Vitals

Today's Low:
₹624.15
Today's High:
₹642.85
Open Price:
₹626.45
52W Low:
₹316.7304
52W High:
₹498
Prev. Close:
₹628.7
Volume:
70941

Company Statistics

Market Cap.:
₹499.12 billion
Book Value:
164.258
Revenue TTM:
₹164.33 billion
Operating Margin TTM:
15.79%
Gross Profit TTM:
₹95.80 billion
Profit Margin:
12.54%
Return on Assets TTM:
5.64%
Return on Equity TTM:
11.32%

Company Profile

Zydus Lifesciences Ltd had its IPO on under the ticker symbol ZYDUSLIFE.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Zydus Lifesciences Ltd has a staff strength of 23,000 employees.

Stock update

Shares of Zydus Lifesciences Ltd opened at ₹626.45 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹624.15 - ₹642.85, and closed at ₹627.65.

This is a -0.17% slip from the previous day's closing price.

A total volume of 70,941 shares were traded at the close of the day’s session.

In the last one week, shares of Zydus Lifesciences Ltd have increased by +1.14%.

Zydus Lifesciences Ltd's Key Ratios

Zydus Lifesciences Ltd has a market cap of ₹499.12 billion, indicating a price to book ratio of 2.4927 and a price to sales ratio of 2.6344.

In the last 12-months Zydus Lifesciences Ltd’s revenue was ₹164.33 billion with a gross profit of ₹95.80 billion and an EBITDA of ₹33.01 billion. The EBITDA ratio measures Zydus Lifesciences Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Zydus Lifesciences Ltd’s operating margin was 15.79% while its return on assets stood at 5.64% with a return of equity of 11.32%.

In Q4, Zydus Lifesciences Ltd’s quarterly earnings growth was a positive 25.8% while revenue growth was a positive 19.4%.

Zydus Lifesciences Ltd’s PE and PEG Ratio

Forward PE
21.5983
Trailing PE
24.1361
PEG

Its diluted EPS in the last 12-months stands at ₹20.43 per share while it has a forward price to earnings multiple of 21.5983 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zydus Lifesciences Ltd’s profitability.

Zydus Lifesciences Ltd stock is trading at a EV to sales ratio of 2.7899 and a EV to EBITDA ratio of 12.5742. Its price to sales ratio in the trailing 12-months stood at 2.6344.

Zydus Lifesciences Ltd stock pays annual dividends of ₹0 per share, indicating a yield of 0.51% and a payout ratio of 12.24%.

Balance sheet and cash flow metrics

Total Assets
₹256.29 billion
Total Liabilities
₹61.21 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
12.24%

Zydus Lifesciences Ltd ended 2024 with ₹256.29 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹256.29 billion while shareholder equity stood at ₹166.65 billion.

Zydus Lifesciences Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹61.21 billion in other current liabilities, 1012000000.00 in common stock, ₹0 in retained earnings and ₹54.06 billion in goodwill. Its cash balance stood at ₹4.55 billion and cash and short-term investments were ₹17.48 billion. The company’s total short-term debt was ₹21,373,000,000 while long-term debt stood at ₹2.89 billion.

Zydus Lifesciences Ltd’s total current assets stands at ₹97.12 billion while long-term investments were ₹0 and short-term investments were ₹12.93 billion. Its net receivables were ₹37.25 billion compared to accounts payable of ₹18.03 billion and inventory worth ₹34.05 billion.

In 2024, Zydus Lifesciences Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Zydus Lifesciences Ltd paid ₹0.12 in dividends in 2024.

Other key metrics

Current Trading Price
₹627.65
52-Week High
₹498
52-Week Low
₹316.7304
Analyst Target Price

Zydus Lifesciences Ltd stock is currently trading at ₹627.65 per share. It touched a 52-week high of ₹498 and a 52-week low of ₹498. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹623.78 and 200-day moving average was ₹509.43 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 7538.6% of the company’s stock are held by insiders while 1354.4% are held by institutions.

Frequently Asked Questions About Zydus Lifesciences Ltd

The stock symbol (also called stock or share ticker) of Zydus Lifesciences Ltd is ZYDUSLIFE

The IPO of Zydus Lifesciences Ltd took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
₹20.38
0.38
+1.9%
₹2980.5
-61.9
-2.03%
₹316.3
-21.65
-6.41%
₹11.04
0.13
+1.19%
₹0.84
0
0%
₹28.7
0.19
+0.67%
₹235.55
-25.05
-9.61%
₹150.65
-3.89
-2.52%
₹3792
-143
-3.63%
₹652.7
-19.05
-2.84%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

Address

Zydus Corporate Park, Ahmedabad, India, 382481